文献速递妇科

首创CDK4抑制剂在体外、离体和体内均显示抗卵巢癌疗效

A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2020-09-18

研究评估首创CDK4抑制剂CDDD2-94(以帕博西利为对照)对卵巢癌的抗增殖活性及机制,并在A2780荷瘤裸鼠中验证安全性和疗效。CDDD2-94阻滞G1/G0期、诱导衰老并抑制Rb功能正常的卵巢癌细胞增殖,与mTOR、MEK、PI3K或PARP抑制剂联用表现协同抗增殖活性。CDDD2-94单药及联合依维莫司可延缓肿瘤生长并显著延长小鼠生存,且对淋巴细胞和中性粒细胞影响小。

要点

  • CDDD2-94靶向CDK4,阻滞G1/G0期并诱导Rb功能正常的卵巢癌细胞衰老。
  • CDDD2-94与mTOR、MEK、PI3K或PARP抑制剂联用表现协同抗增殖活性。
  • CDDD2-94单药及联合依维莫司延缓小鼠肿瘤生长并显著延长生存。

核心结论

  • 鉴于CDDD2-94对CDK4的高特异性和低毒性的优良抗肿瘤疗效,其有潜力开发为卵巢癌的单独用药或与靶向治疗联用。

研究设计与样本

  • 体外及离体研究采用MTT法、细胞周期与凋亡分析、蛋白质印迹、衰老及集落形成实验评估CDDD2-94(以帕博西利为对照)的抗增殖活性与机制。
  • 体内安全性和疗效研究在A2780荷瘤裸鼠中进行。
  • 在A2780和OVCAR5卵巢癌细胞中评估CDDD2-94与mTOR、MEK、PI3K或PARP抑制剂的联合作用。

主要发现

  • CDDD2-94阻滞G1/G0细胞周期、诱导衰老并抑制Rb功能正常的卵巢癌细胞增殖,与CDK4靶向机制一致。
  • CDDD2-94与mTOR、MEK、PI3K或PARP抑制剂表现协同抗增殖活性。
  • 帕博西利导致淋巴细胞和中性粒细胞数量显著减少,而CDDD2-94影响很小。
  • CDDD2-94单药及联合依维莫司延缓肿瘤生长并显著延长小鼠生存。

临床怎么用

  • 作者认为CDDD2-94有潜力开发为卵巢癌的单独用药或与靶向治疗联用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cyclin-dependent kinases 4 and 6 (CDK4/6) are fundamental drivers of the cell cycle and are involved in the initiation and progression of various cancers. Deregulation of the CDK4/6-cyclin D-retinoblastoma (Rb) pathway is common in ovarian cancer and is associated with an aggressive phenotype and poor prognosis. Patients with advanced ovarian cancer whose tumor demonstrates Rb-positivity, a low expression of p16 and overexpression of cyclin D1 are most likely to benefit from CDK4/6 inhibition. MATERIALS AND METHOD: Anti-proliferative activity and mechanistic investigations for CDDD2-94, employing palbociclib as comparator, were evaluated by MTT assay, cell cycle and apoptosis analysis, western blotting as well as senescence and colony formation assay. In vivo safety and efficacy studies were done in A2780 tumor-bearing nude mice. Combinations of CDDD2-94 with mTOR, MEK, PI3K or PARP inhibitors were evaluated in A2780 and OVCAR5 ovarian cancer cells. RESULTS: Consistent with a CDK4-targeted mechanism, CDDD2-94 arrested the G1/G0 cell cycle, induced senescence and inhibited the proliferation of Rb-proficient ovarian cancer cells. CDDD2-94 exhibited synergistic anti-proliferative activities with mTOR, MEK, PI3K or PARP inhibitors. Importantly, unlike palbociclib which caused significant reductions in the number of lymphocytes and neutrophils, CDDD2-94 had little effect. CDDD2-94, as single agent and in combination with everolimus, delayed tumor growth and significantly increased survival of mice. CONCLUSION: Given its high specificity in targeting CDK4 and excellent anti-tumor efficacy with low toxicity, CDDD2-94 has potential to be developed as a standalone agent or in combination with targeted therapeutics for the treatment of ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Bantie L, Tadesse S, Likisa J, et al. A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer. Gynecol Oncol. 2020. PMID: 32958271. doi:10.1016/j.ygyno.2020.09.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。